Trial Profile

A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cinrebafusp alfa (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Colorectal cancer; Gastric cancer; Gynaecological cancer; Malignant melanoma; Oesophageal cancer; Pancreatic cancer; Rectal cancer; Salivary gland cancer; Solid tumours; Urogenital cancer
Focus Adverse reactions; First in man
Sponsors Pieris Pharmaceuticals

Most Recent Events

18 Jan 2022 Status changed from recruiting to completed.
10 Apr 2021 According to a Pieris Pharmaceuticals media release, data from this study was presented at the American Association for Cancer Research (AACR) Virtual Congress 2021.
10 Apr 2021 Results published in the Pieris Pharmaceuticals media release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com